Abstract: Anomaly detection based on system logs plays an important role in intelligent operations, which is a challenging task due to the extremely complex log patterns. Existing methods detect ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Somerville company aims to ...